(Sharecast News) - Fevertree: Barclays upgrades to buy with a target price of 2,500p.
Taylor Wimpey: Berenberg reiterates buy with a target price of 210p.
Centamin: Berenberg reiterates buy with a target price of 133p.
Litigation Capital Management: Canaccord reiterates buy with a target price of 94p.
Helium One Global: Canaccord initiates at speculative buy with a target price of 20p.
Ultra Electronics: JP Morgan reiterates overweight with a target price of 2,500p.
Croda: JP Morgan reiterates underweight with a target price of 5,550p.
AstraZeneca: Deutsche Bank reiterates buy with a target price of 10,200p.
GSK: Deutsche Bank reiterates sell with a target price of 1,150p.
Reckitt Benckiser: Barclays reiterates overweight with a target price of 9,100p.
Cineworld: Peel Hunt downgrades to hold with a target price of 105p.
Knights: Liberum reiterates buy with a target price of 500p.
Ergomed: Numis downgrades to add with a target price of 1,330p.
Bunzl: RBC Capital Markets upgrades to sector perform with a target price of 2,270p.
Astrazeneca (AZN)
Centamin PLC (CEY)
Fevertree (FEVR)
Glaxosmithkline (GSK)
Bunzl (BNZL)
Taylor Wimpey (TW.)
Croda International (CRDA)
Knights Group . (KGH)
Litigation Cap. (LIT)
Helium One (HE1)29 Apr 2024 22:52
J&J, Bristol Myers lose challenges to US drug price negotiation program
April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negoti...
